Projected Income Statement: Axsome Therapeutics, Inc.

Forecast Balance Sheet: Axsome Therapeutics, Inc.

Forecast Balance Sheet - Axsome Therapeutics, Inc.
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt 1 -37.4 -107 -208 -135 -135 -153 -426 -818
Change - -186.1% -94.39% 35.1% 0% -13.18% -178.43% -92.02%
Announcement Date 01/03/22 27/02/23 20/02/24 18/02/25 23/02/26 - - -
1USD in Million
Estimates

Cash Flow Forecast: Axsome Therapeutics, Inc.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
CAPEX 1 0.3076 0.7021 0.582 0.27 0.48 1.93 5.195 7.91
Change - 128.29% -17.11% -53.61% 77.78% 302% 169.22% 52.27%
Free Cash Flow (FCF) 1 -108.5 -117.2 -145.7 -128.7 -93.88 -187.4 351 702.4
Change - -8% -24.27% 11.66% 27.04% -99.58% 287.31% 100.13%
Announcement Date 01/03/22 27/02/23 20/02/24 18/02/25 23/02/26 - - -
1USD in Million
Estimates

Forecast Financial Ratios: Axsome Therapeutics, Inc.

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

        
EBITDA Margin (%) - -350.53% -83.15% -70.95% -25.04% -12.51% 9.06% 17.33%
EBIT Margin (%) - -359.33% -85.67% -72.74% -26.12% -13.55% 13.35% 32.12%
EBT Margin (%) - -373.99% -88.06% -74.45% -28.77% -14.37% 13.16% 31.33%
Net margin (%) - -373.99% -88.41% -74.47% -28.69% -14.14% 12.51% 28.45%
FCF margin (%) - -234.25% -53.83% -33.36% -14.7% -19.68% 24.22% 34.16%
FCF / Net Income (%) 83.23% 62.64% 60.89% 44.8% 51.25% 139.13% 193.54% 120.08%

Profitability

        
ROA -95.21% -89.27% - -49.66% -29.11% -17.91% 13.18% 34.94%
ROE -201.51% -298.97% -159.21% -231.63% -252.11% -272.88% -23.2% -259.76%

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) - 1.4% 0.22% 0.07% 0.08% 0.2% 0.36% 0.38%
CAPEX / EBITDA (%) -0.25% -0.4% -0.26% -0.1% -0.3% -1.62% 3.96% 2.22%
CAPEX / FCF (%) -0.28% -0.6% -0.4% -0.21% -0.51% -1.03% 1.48% 1.13%

Items per share

        
Cash flow per share 1 -2.877 -2.866 -3.194 -2.68 -1.878 -0.553 6.037 11.19
Change - 0.39% -11.45% 16.09% 29.94% 70.55% 1,191.62% 85.37%
Dividend per Share 1 - - - - - - - -
Change - - - - - - - -
Book Value Per Share 1 0.4155 2.519 4.033 1.172 1.735 1.817 4.128 11.18
Change - 506.16% 60.14% -70.95% 48.13% 4.74% 127.14% 170.73%
EPS 1 -3.47 -4.6 -5.27 -5.99 -3.68 -2.585 3.296 10.32
Change - -32.56% -14.57% -13.66% 38.56% 29.75% 227.48% 213.25%
Nbr of stocks (in thousands) 37,692 43,426 47,320 48,462 50,413 52,600 52,600 52,600
Announcement Date 01/03/22 27/02/23 20/02/24 18/02/25 23/02/26 - - -
1USD
Estimates
2026 *2027 *
P/E -54.8x 43x
PBR 78x 34.3x
EV / Sales 7.67x 4.85x
Yield - -

EPS & Dividend

EPS & Dividend - Axsome Therapeutics, Inc.


Y-o-Y evolution of P/E

Valuation ratios - P/E - Axsome Therapeutics, Inc.
 

Year-on-year evolution of the Yield

Valuation ratios - Yield - Axsome Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Axsome Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
141.69USD
Average target price
265.86USD
Spread / Average Target
+87.63%
  1. Stock Market
  2. Stocks
  3. AXSM Stock
  4. Financials Axsome Therapeutics, Inc.